ACT-101
Analyzing The Annual Report-2009 of BEXIMCO PHARMACEUTICALS LTD Course
Financial Accounting (ACT 101)
Semester
Summer 2010
Prepared for
Mr. Polash Kumar Kundu
Lecturer
Department of Business Administration
Prepared by
Habibul Basher 2009-3-10-037
Fahad Bin Reza 2009-3-10-054
Ayaz Mohammad Arman 2009-3-10-073
Section: 05
Date of submission: 08 August 2010
East West University
BEXIMCO PHARMACEUTICALS LTD BEXIMCO PHARMACEUTICALS LTD (BPL) Belongs to Beximco Group, the largest private industrial conglomerate in Bangladesh. Here we analyze the financial statement - 2009 of BPL and try to make a logical thought for the potential share holders or share market investors that they should buy the BPL share or not. The increase or decrease percentage of BPLs’ financial statement – 2009 is following:
Accounts Name
2009
2008
Percentage
Net Sales Revenue
4,868,254,915
4,010,167,059
21
Cost of Goods Sold
2,566,206,626
2,002,871,181
28
Gross Profit
2,302,048,289
2,007,295,878
15
Operating Expenses
Administrative Expenses
215,192,547
153,464,243
29
40
Selling, Marketing and Distribution Expenses
1,085,573,331
855,036,787
27
Net Profit
624,740,307
545,341,273
15
Non-current Assets
12,975,195,529
11,957,773,787
09
Current Assets
6,916,737,893
2,861,891,654
142
Total Assets
19,891,933,422
14,819,665,441
34
Shareholders’ Equity
10,855,706,614
10,450,202,145
4
Non-current Liabilities
6,684,775,166
1,767,431,029
278
Current Liabilities & Provision
2,321,451,642
2,602,032,267
-12
Total Liabilities & Shareholders Equity
19,891,933,422
14,819,665,441
34
The annual Report-2009 of BPL shows that its net sales revenue is increased 21% than 2008. In the same time we can see that its Cost of Goods Sold is 28% higher than 2008, for this reason there gross profit is increased only 15%. It is not a good sign for a company. BPLs sale is increased only 21% but its operating expenses is
Financial Accounting (ACT 101)
Semester
Summer 2010
Prepared for
Mr. Polash Kumar Kundu
Lecturer
Department of Business Administration
Prepared by
Habibul Basher 2009-3-10-037
Fahad Bin Reza 2009-3-10-054
Ayaz Mohammad Arman 2009-3-10-073
Section: 05
Date of submission: 08 August 2010
East West University
BEXIMCO PHARMACEUTICALS LTD BEXIMCO PHARMACEUTICALS LTD (BPL) Belongs to Beximco Group, the largest private industrial conglomerate in Bangladesh. Here we analyze the financial statement - 2009 of BPL and try to make a logical thought for the potential share holders or share market investors that they should buy the BPL share or not. The increase or decrease percentage of BPLs’ financial statement – 2009 is following:
Accounts Name
2009
2008
Percentage
Net Sales Revenue
4,868,254,915
4,010,167,059
21
Cost of Goods Sold
2,566,206,626
2,002,871,181
28
Gross Profit
2,302,048,289
2,007,295,878
15
Operating Expenses
Administrative Expenses
215,192,547
153,464,243
29
40
Selling, Marketing and Distribution Expenses
1,085,573,331
855,036,787
27
Net Profit
624,740,307
545,341,273
15
Non-current Assets
12,975,195,529
11,957,773,787
09
Current Assets
6,916,737,893
2,861,891,654
142
Total Assets
19,891,933,422
14,819,665,441
34
Shareholders’ Equity
10,855,706,614
10,450,202,145
4
Non-current Liabilities
6,684,775,166
1,767,431,029
278
Current Liabilities & Provision
2,321,451,642
2,602,032,267
-12
Total Liabilities & Shareholders Equity
19,891,933,422
14,819,665,441
34
The annual Report-2009 of BPL shows that its net sales revenue is increased 21% than 2008. In the same time we can see that its Cost of Goods Sold is 28% higher than 2008, for this reason there gross profit is increased only 15%. It is not a good sign for a company. BPLs sale is increased only 21% but its operating expenses is